Skip to search formSkip to main contentSkip to account menu

CP 336156

Known as: CP-336,156 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
  • Drugs in R&D
  • 2005
  • Corpus ID: 42955649
Lasofoxifene [CP 336156] is a potent, nonsteroidal, tissue-selective estrogen receptor modulator (SERM). It has the bone-sparing… 
Highly Cited
2004
Highly Cited
2004
Neuroprotective effects of estradiol are well characterized in animal experimental models. However, in humans, the outcome of… 
2003
2003
2002
2002
Estrogen replacement therapy is reported to reduce the incidence of vertebral fractures in postmenopausal women, however, its… 
Highly Cited
2001
Highly Cited
2001
The purpose of this study was to evaluate if long‐term (6 months) treatment with lasofoxifene (LAS), a new selective estrogen… 
Review
2000
Review
2000
Selective oestrogen receptor modulators (SERMs) are structurally diverse non-steroidal compounds that bind to oestrogen receptors… 
Highly Cited
2000
Highly Cited
2000
It has been well documented that selective estrogen receptor modulators (SERMs) can prevent bone loss in ovariectomized rats and… 
2000
2000
  • P. Neven
  • European journal of cancer
  • 2000
  • Corpus ID: 40941709
Highly Cited
1998
Highly Cited
1998
We have discovered a new, nonsteroidal, potent estrogen agonist/antagonist, CP-336,156. CP-336,156 binds selectively and with… 
Highly Cited
1998
Highly Cited
1998
We have discovered a new, nonsteroidal, potent estrogen agonist/antagonist, CP-336,156. CP-336,156 binds selectively and with…